Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$12.05M$12.05M+8.3% vs Q1 2023 Net Income-$12.83M-$12.83MN/M vs Q1 2023 EPS Diluted-$0.17-$0.17N/M vs Q1 2023 Operating Income-$8,957,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,413,000N/M Margins · derivedOperating margin-74.3%−33.0 pt vs Q1 2023
Net margin-106.4%−178.9 pt vs Q1 2023
ended Mar 31, 2024 · filed May 7, 2024 · 37 d after period end